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Abstract 
Magnetic resonance imaging (MRI) has a leading place in medicine as an imaging tool of high 
resolution for anatomical studies and diagnosis of diseases, in particular for soft tissues that 
cannot be accessible by other modalities. Many researches are thus focused on improving the 
images obtained with MRI. This technique has indeed poor sensitivity, which can be 
compensated by using a contrast agent (CA). Today, the clinically approved CAs on market are 
solely based on gadolinium complexes that may induce nephrogenic systemic fibrosis (NSF) for 
patients with kidneys failure, while more recent studies on healthy rats also showed Gd-retention 
in the brain. Consequently, researchers try to elaborate other types of safer MRI CA like 
manganese-based complexes. 
In this context, the synthesis of the Mn2+ complexes of four 12-membered pyridine-containing 
macrocyclic ligands based on the pyclen core was accomplished and described herein. Then, the 
properties of these Mn(II) complexes were studied by two relaxometric methods, 17O NMR 
spectroscopy and 1H NMR dispersion profiles. The time of residence (τM) and the number of 
water molecules (q) present in the inner-sphere of coordination were determined by these two 
experiments. The efficacy of the pyclen-based Mn(II)  complexes as MRI CAs was evaluated by 
proton relaxometry at a magnetic field intensity of 1.41 T near those of most medical MRI 
scanners (1.5 T). Both the 17O NMR and the NMRD profiles indicated that the four hexadentate 
ligands prepared herein left one vacant coordination site to accommodate one water molecule 
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rapidly exchanging, in around 6 ns. Furthermore, it has been shown that the presence of an 
additional amide bond formed when the paramagnetic complex is conjugated to a molecule of 
interest does not alter the inner-sphere of coordination of Mn which remains monohydrated. 
These complexes exhibit r1 relaxivities large enough to be used as clinical MRI CAs (1.7–
3.4 mM-1·s-1, at 1.41 T and 37°C). 
Introduction 
Gadolinium complexes are currently the main contrast agents (CAs) authorized and used in the 
clinics for medical diagnosis by Magnetic Resonance Imaging (MRI). In fact, this powerful non-
invasive imaging technique often requires the use of a CA to compensate its lack of sensitivity. 
Different classes of CAs have been developed for MRI, yet gadolinium complexes are by far the 
most used in the clinical field thanks to their property to decrease the water longitudinal 
relaxation time of protons, highlighting on the images the areas where the CA is accumulated.1 
Nevertheless, some researches have demonstrated since more than a decade that the injection of 
gadolinium complexes to patients with kidneys failure can trigger apparition of a disease called 
nephrogenic systemic fibrosis (NSF).2–5 This is particularly true for linear gadolinium complexes 
based on acyclic ligands such as Gd-DTPA (diethylenetriamine penta acetic acid gadolinium 
complex) that are less thermodynamically and kinetically stable than those based on macrocyclic 
complexes such as Gd-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
gadolinium complex). Therefore, some marketed Gd-based CAs (GBCAs) are no longer 
recommended for these patients.2,3,6 In addition, more recent studies have shown accumulation in 
the brain of gadolinium CAs in subjects with normal renal function.7,8 Further investigations 
were carried out on rats to compare macrocyclic (Gadoteridol®) with linear (Gadodiamide®) 
marketed agents and to quantify the Gd-species retained in the brain. It was concluded that 
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Gadoteridol® was much less retained than Gadodiamide® and fully detected in the urines as its 
intact and soluble Gd-species, whereas Gadodiamide® was found mostly as insoluble species.9,10 
This situation explains that scientists are much interested in finding a safer next generation of 
MRI CAs based on Gd-free alternatives, and one of them could be the use of manganese-based 
CAs.11,12 Manganese ions are essential and naturally present in the body under the high-spin 
form of Mn2+ or Mn3+ with 5 or 4 unpaired d-orbital electrons, respectively. The normal 
physiological concentration of manganese in the serum of healthy subjects is about 0.05–
0.12 µg/dL (9–22 µM)13, and part of its important biological role in the organism is to act as a 
cofactor activating certain enzymes or as a constituent in metalloenzymes. Manganese ions also 
play a role in the development of the immune and nerve systems function and in the regulation of 
the amount of vitamins and sugar in the blood.13,14 The first use of manganese as MRI CA was 
an oral formulation containing liposome-encapsulated MnCl2 salt (LumenHance®) indicated for 
gastrointestinal examinations. However, several studies have shown that too high doses of free 
manganese ions could induce a neurodegenerative disorder called manganism, a disease with 
symptoms similar to those of the Parkinson’s disease. Despite toxicity of free Mn2+ ions, 
manganese enhanced MRI (MEMRI) using MnCl2 is used for preclinical studies in mice for 
brain15 or lung16 model tumors. To avoid adverse effects, manganese complexes have been 
developed, and the second manganese-based CA  approved by the Food and Drug 
Administration (FDA) in 1997 was manganese dipyridoxyl diphosphate (Mn-DPDP, Teslascan®, 
Figure 1) for use as a liver specific hepatobiliary CA.17 This structure is based on a linear ligand 
and has low thermodynamic and kinetic stabilities with consequently a certain amount of free 
manganese ions released in vivo. The efficacy of the Mn-DPDP as a MRI CA is quite low 
because the ligand does not allow a coordination bond with one water molecule in the 
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inner-sphere of metal coordination. The interest of such a candidate as CA comes therefore from 
the part of the released manganese ions whose relaxivity is 2.8 s-1·mM-1 at 20 MHz and 40°C in 
aqueous solution; as a point of comparison, the relaxivity of Gd-DOTA which is a well-known 
commercialized macrocyclic CA is 3.5 s-1·mM-1 at 20 MHz and 3.1 s-1·mM-1 at 60 MHz and 
37°C.18,19 As a result and for safety concerns (potential toxicity of released free Mn2+), Mn-
DPDP is no longer commercialized for clinical use, so there is still need for Gd-free alternatives, 
with higher thermodynamic stability and kinetic inertness in order to avoid the release of free 
manganese ions in vivo, and with a higher efficacy to be competitive with GBCAs.4,5,11,19 As a 
possibility, researchers examined if Mn-porphyrins, where the manganese cation is the center of 
a heme ring, can be used as MRI CAs: they found very high longitudinal and transverse 
relaxivities, of 9.33 and 12.0 s-1·mM-1 at 3T (20°C) respectively, thereby enabling MRI detection 
in vivo of Mn-labelled cells.20,21 Porphyrins exhibit multiple advantages such as being able to 
stabilize manganese in its higher oxidation states Mn(III) or even Mn(V), needing to add a 
reducing agent in the medium such as sodium dithionite (Na2S2O4) to insure the Mn(II) state.22 
However, their synthesis is delicate in the perspective of scale-up production for an envisioned 
clinical use. Moreover, such compounds are highly light-sensitive, which is why they are 
intensively studied in a context of therapeutic agents for photodynamic therapy. Slightly larger 
ring-shaped ligands called texaphyrins complexing Mn2+ were recently proposed as bimodal CAs 
(MRI and photoacoustic imaging).23 On the other hand, purely inorganic Mn-based nanoparticles 
(NPs) like antiferromagnetic MnO or paramagnetic Mn-doped ferrocyanide NPs (Prussian blues) 
were also tested as potential CAs for MRI.24   
In view of this effort of the community to develop macrocyclic ligands with high affinity for 
Mn(II) and high efficiency as MRI CAs25, this report explores the potential of four Mn(II) 
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complexes based on the pyclen core (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-
triene) and carrying an additional site for the conjugation to a molecule of interest, for instance a 
chemotoxic drug or a polymeric vector. Pyclen is an interesting 12-membered macrocyclic 
structure that incorporates a N-pyridyl donor that rigidifies and pre-organizes the ligand 
coordinating groups (in particular rendering the 4 nitrogen atoms coplanar), an attribute that can 
improve the kinetic inertness of the resulting complex. Pyclen ligands have been reported 
recently for coordination of luminescent lanthanide cations to develop optical probes for near-
infrared imaging.26 The pyridine subunit also provides enhanced degree of lipophilicity that can 
promote mixed renal and hepatobiliary clearances, another interesting attribute in the context of 
patients with reduced kidney function. The choice of pyclen-based chelating agents was also 
guided by their availability as “tailor-made” synthetic chelators prepared according to a versatile 
and potentially up-scalable strategy practiced by us and others which consists in assembling two 
synthons previously “dressed” with all the final functionalities required: the donor groups to 
satisfy the electronic demand of the paramagnetic ion, and an additional function to allow its 
conjugation to a molecule of interest.27–31 Since Mn(II) complexes typically have coordination 
numbers of 6 or 7, ligands for Mn(II) cannot exceed hexadenticity to allow the exchange of at 
least one water co-ligand in its inner-sphere that is a crucial parameter to insure interesting 
relaxometric properties for MRI applications. Consequently, it was necessary to cleverly 
functionalize the pyclen derivative in order to limit to 6 its coordination bonds with Mn2+ while 
providing a sufficiently high degree of coordination to preserve satisfying thermodynamic 
stability of the complex. 
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Figure 1. Structures of the ligands discussed in this work : (A) DPDP17, (B) PCMA and PCMP29 
, (C) PCTA, PC3AMH, PC3AMGly, and PC3AMPip,32 and (D) PC2A, PC2A-EA, and PCTA33  
The pyclen ([12]PyN4) macrocyclic core is now recognized to form efficient chelators for the 
Mn2+ cation complexation, and some studies can be found on the interest of such pyridine-
containing (PC) ligands (figure 1). Drahos et al. have studied the influence on the 
thermodynamic stability, the kinetic inertness, the redox potential, and the 1H and 17O relaxation 
rates by modifying the nature of the coordinating group on one arm of the macrocycle. They 
found that the mono-functionalized pyclens PCMA and PCMP with an acetate or a methyl 
phosphonate pendant arm give ternary hexacoordinate Mn2+ complexes accommodated with one 
water co-ligand (Figure 1), both of them being rather stable.29 With a similar purpose, Garda et 
al. studied the influence on the proton relaxometry, the thermodynamic stability and the kinetic 
inertness of the presence of a primary, a secondary or a tertiary amide instead of the carboxylate 
functions of the PCTA which is a well know pyclen derivative.32 However, the corresponding 
Mn(II)-complexes show quite low relaxivities, less than 2 s-1·mM-1 at 37°C and 20 MHz. In a 
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more recent study, Botar et al. have developed a pH-responsive CA, [Mn(PC2A-EA)] stable and 
inert, with a maximum relaxivity at acidic pH of 3.5 s-1·mM-1 at 20 MHz and 37°C. 33  All these 
results show that much efforts is still to be done to try increasing the efficacy of Mn-complexes 
as MRI contrast agents (Figure 1). 
In this work, it was decided to study a series of four N4O2 hexadentate pyclen chelators 
including three structures carrying an additional function grafted onto the pyridine ring to allow 
conjugation to a molecule of interest (Figure 2). The “naked” complex MnL1H where –H 
designates absence of substituent in ortho position of the pyridine ring will be used as a reference 
to evaluate the impact of this additional subunit on the relaxometric properties of the 
corresponding Mn-complexes. Our previous work showed indeed that the functionalization of 
the carboxylate moiety into an amide bond on the pyridine arm of Gd-PCTA leads to a loss of 
one water molecule in the inner-sphere, giving q = 1 instead of q = 2.31 The syntheses are 
reported herein, together with the full relaxometric characterization of the corresponding Mn-
complexes in order to have a complete understanding of their efficiency as MRI CAs (Figure 2).  
   
Figure 2. Structure of the four Mn-complexes synthesized and studied in this work MnL1H: 
MnPy(COO-)2-H; MnL2COO- : MnPy(COO-)2-OCH2COO-; MnL3CH: MnPy(COO-)2-
OCH2CONHCH2CCH and MnL4NH3+: MnPy(COO-)2-OCH2CONH(CH2)2NH3+. 
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Results and discussion 
Synthesis of the pyclen-based Mn2+ complexes 
The synthetic route to triamine 5b is similar to that we described previously for the analogous 
compound bearing three acetate arms (Scheme 1).31 The selectively N,N''-protected 
diethylenetriamine derivative 2 was reacted in tetrahydrofuran (THF) with slight excess of both 
benzyl chloroformate and diisopropylethylamine (DIPEA) to afford the fully protected 
compound 3 in 94% yield. The next two steps, grafting of the acetate arms onto the secondary 
sulfonamides followed by cleavage of the o-nitrobenzenesulfonyl (Nosyl) protecting groups, 
were carried out in one-pot in warmed acetonitrile. For each of the two steps, the total 
consumption of both the starting materials and the monofunctionalized intermediate (i.e. 3 and 
4a for the first step; 4b and 5a for the second one) was carefully monitored (TLC and/or mass 
spectroscopy) and led to synthon 5b with a yield of 85%. 
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Scheme 1. Synthesis of (a) NaOH, Nos-Cl, diethylether, THF, r.t. overnight (b) Cbz-Cl, DIPEA, 
THF, r.t. 1h30 (ci)BrCH2CO2tBu, K2CO3, CH3CN, reflux 3-5h (cii)PhSH, K2CO3, 60°C 2-4h 
As previously described for PCTA derivatives, the pyclen macro-ring formation was achieved 
by reacting the triamine 5b with a small excess of 2,6-dibromomethylpyridine 6a-b under 
heterogeneous conditions in refluxing acetonitrile at moderate dilution (0.01M) with sodium 
carbonate as scavenger (Scheme 2).31 In such conditions, the corresponding macrocycles 7a-b 
were isolated in 39 and 64% yields respectively.  
 
Scheme 2. Synthesis of (d) Na2CO3, CH3CN, reflux 
The macrocyclic pyclen skeleton built, successive step-by-step deprotections were necessary in 
order to allow selective grafting of different molecules of interest on the additional pendant 
group attached on the pyridine moiety and on the macrocycle (Scheme 3-5).  
The carboxybenzyl group of compound 7a-b was smoothly removed by a pallado-catalyzed 
hydrogenolysis under an atmospheric pressure of H2 at room temperature and afforded 
compound 8a-b (Scheme 3). The reaction can be performed in MeOH and EtOH but using of 
MeOH for 8b can lead to transesterification. However, obtaining a mixture (if partial) of both 
methyl and ethyl esters does not impact the next step of saponification. The controlled removal 
of the ethyl ester group of compound 8b was then achieved by mild saponification with NaOH 
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and provided the corresponding carboxylate 9 in 67% yield. The tert-butyl ester functions of the 
prochelators 8a and 9 were removed by treatment with trifluoroacetic acid and led to the 
pyclen-based chelating agents 10a-b that were finally complexed to Mn(II) by reaction with an 
equimolar amount of manganese dichloride tetrahydrate at controlled pH (ca 5-6) to give the 




Scheme 3. Synthesis of (e) Pd/C, EtOH or MeOH, H2 atm, r.t. overnight (f) NaOH, EtOH, r.t. 7h 
(g) and (h) CF3CO2H, CH2Cl2, r.t. overnight (i) MnCl2·4H2O, H2O, pH 5-6, 40°C overnight. 11a 
is compound (MnL1H), 11b is compound (MnL2COO-). 
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Compound 9 has an additional carboxylic acid function on the pyridine subunit to allow 
subsequent conjugation to an amine function of different molecules of interest (Scheme 3). As 
previously shown by us for a bifunctional PCTA chelator prepared to complex Gd3+,31 the 
resulting amide bond can act as an additional donor group so that the overall denticity of the 
chelator is increased, and the coordination of water molecule as co-ligand in the inner-sphere of 
the paramagnetic center can be compromised which has a negative impact on the relaxivity of 
the chelate. Consequently, it was decided to study the impact of this additional amide bond on 
the relaxivity of the Mn2+ complexes.  
Both compounds 14 and 17 were designed with a dual purpose: to study the influence of an 
additional pendant amide bond on relaxometry, and to vary the function to allow subsequent 
conjugation for forthcoming studies: by click chemistry with Huisgen’s 1,3-cyloaddition on the 
alkyne end-group, or by coupling the primary amine with carboxylic acid groups (Schemes 4-5). 
On the one hand, propargylamine was grafted to compound 9 using the uronium-based 
activating agent HBTU (O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate) and afforded the carbamoyl derivative 12 (over 90 % yield) whose tert-
butyl ester functions were then removed upon treatment with trifluoroacetic acid. The resulting 
pyclen-based chelating agent 13 as trifluoroacetic salt was finally complexed to Mn(II) as 
previously done for 10a-b (Scheme 4).  
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Scheme 4. Synthesis of (j) HBTU, NH2CH2CCH, DIPEA, CH2Cl2, r.t. 4h30 (k) TFA, CH2Cl2, 
r.t. 1 day (l) MnCl2·4H2O, H2O, pH = 5-6, 40°C overnight. The final product is compound 
(MnL3CH). 
On the other hand, the ethyl ester derivative 7b was submitted to aminolysis in ethylenediamine 
at room temperature for 1 hour and led to the expected amido derivative 15 in 58% yield. 
Compound 15 was then submitted to acidolyses with hydrogen bromide in warmed acetic acid to 
cleave both the tert-butyl ester and the carbamate functions and led to the expected ligand 16a in 
72% yield. It is noteworthy that upon treatment with hydrogen chloride in diethyl ether solution 
at room temperature, even repeatedly, only partial cleavage of the benzyloxycarbamate function 
was observed and gave a mixture of the desired compound 16a and of the intermediate 16b (as 
hydrochloride forms). Complexation with Mn2+ finally proceeded very easily, in few minutes at 
room temperature (Scheme 5). 
 




Scheme 5. Synthesis of (m) NH2CH2CH2NH2, r.t. (n) HClanh, Et2O or HBranh, AcOH, 70°C then 
r.t. (o) MnCl2.4H2O, H2O, pH 5-6, r.t.. The final product is compound (MnL4NH3+). 
 In order to ensure that manganese is in the oxidation state +2, the complexations were 
performed under argon atmosphere and a reducing agent, sodium dithionite (approximately 1.3 
eq Na2S2O4), was added to the solutions with the pH maintained between 7 and 8.22  
 
Relaxometric characterization  
Determination of the number of coordinated water molecules  
The determination of the number of water molecules in the inner coordination sphere (q) is 
very important to estimate the efficacy of the complexes as MRI contrast agents, as the 
longitudinal proton relaxivity r1 is directly related to the number of coordinated water molecules, 
in permanent exchange with those of the solvent. Two different techniques were used to 
determine this q parameter for the Mn(II) complexes, developed respectively by E. Gale et al. 
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and J. Peters and C. Geraldes. The first technique is based on 17O NMR spectroscopy where the 
water transverse relaxivity r2 is measured as a function of temperature.34 (Figure 3) The method 
is then based on the maximum 17O transverse relaxivity, r02max, measured in this case at low 
temperature (equation 1). This equation is obtained by different approximations, as explained by 
E. Gale et al., and the r02max measured at 11.75 T lead to the results shown in Table 1. The 
number q is approximately the same for all complexes and close to one.34 To confirm these 
results, a second technique was used, based on the measurement of NMRD profiles (i.e. the 
water proton longitudinal relaxivity r1 as a function of magnetic field or proton resonance 
frequency) at 25°C, developed by J. Peters and C. Geraldes.35 (Figure 4) This is based on another 
equation related to the proton longitudinal relaxivity at low field (on the plateau of the NMRD 
profile) and the formula weight (FW) of the complex (equation 2). The results (Table 1) confirm 
the presence of one coordinated water molecule in the inner sphere for the four synthesized 
complexes. The slight difference between the results coming from the two techniques can be 
explained by the fact that both methods rely on different approximations. The presence of one 
coordinated water molecules is an interesting result since it shows that the presence of the arm on 
the pyridine moiety, with or without amide bond, does not change the number of coordinated 
water molecules, meaning that this appended functionality does not participate to the 
coordination bounds with the manganese ion. It will thus allow further grafting of molecules of 
interest in a forthcoming study.  
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⎝
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Figure 3. Measurements of the 17O water transverse relaxivity versus inverse of temperature, 
at 11.75 T, in the presence of the different Mn-complexes at 2.06 mM (MnL1H, triangles), 
2.58 mM (MnL2COO-, stars), 2.05 mM (MnL3CH, circles) and 1.21 mM (MnL4NH3+, 
squares) concentration in order to determine the number of inner sphere water molecule (q) 
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Figure 4. NMRD profiles at 25°C in order to determine the number of inner sphere water 
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molecule (q) from Formula (2) derived in reference 35 as a function of the plateau value (r1p) at 
low frequency and the formula weight (FW) for the four complexes: MnL1H (triangles), 
MnL2COO- (stars), MnL3CH (circles) and MnL4NH3+ (squares). 
 
Table 1. Evaluation of the number of coordinated water molecules in the inner sphere for all 
complexes by two different techniques  
 r02max (s-1·mM-1) 
(67.8 MHz) 
q (Eq. 1) r1p (s-1·mM-1) 
(25°C and 
0.02 MHz) 
q (Eq. 2) 
MnL1H 419.2 0.82 ± 0.2 7.7 1.25 ± 0.4 
MnL2COO- 458.4 0.90 ± 0.2 8.3 1.30 ± 0.4 
MnL3CH 473.4 0.93 ± 0.2 9.4 1.35 ± 0.4 
MnL4NH3+ 478.6 0.94 ± 0.2 10.0 1.42 ± 0.4 
 
 
Determination of the exchange rate of the coordinated water molecule  
The technique which allows to determine the lifetime of the coordinated water molecule was 
developed by T. Swift and R. Connick.36 It is based on the measurement of the 17O transverse 
relaxation rate as a function of temperature, as for the determination of q for the Mn(II) 
complexes. (Figure 5). The results (Table 2) show that the coordinated water molecule is in a fast 
exchange regime for the four complexes studied since residence times τM of the order of 6 ns are 
obtained. 
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Figure 5. Measurement of the 17O water transverse relaxation rate as a function of the inverse of 
temperature, at 11.75 T, on solutions of each complex at 2.06 mM (MnL1H, triangles), 2.58 mM 
(MnL2COO-, stars), 2.05 mM (MnL3CH, circles) and 1.21 mM (MnL4NH3+, squares). The 
continuous lines represent fits by the theoretical model developed in reference 36, with the 
parameters displayed in Table 2. 
 
Table 2. Determination of the residence time at 37°C and 11.75 T of the coordinated water 
molecule (𝜏𝜏M), as well as the other parameters characterizing this exchange : A/ħ, the hyperfine 
coupling constant between the oxygen nucleus of the bound water molecule and the Mn2+ ion; τv, 
the correlation time modulating the electronic relaxation of Mn2+; Ev, the activation energy 
related to τv; B, related to the mean-square value of the zero-field splitting energy ∆ (B = 2.4∆2); 
and ∆H≠ and ∆S≠ the enthalpy and entropy of activation, respectively, of the water exchange 






















MnL1H 6.5 ± 0.4 29.7 ± 0.1 7.4 ± 0.2 -39.9 ± 2.5 3.3 ± 0.1 1.4 ± 0.1 33.2 ± 3.1 
MnL2COO- 6.1 ± 0.7 32.4 ± 0.2 16.7 ± 0.3 -39.9 ± 0.8 5.2 ± 0.6 3.2 ± 0.5 36.3 ± 4.6 
MnL3CH 8.4 ± 0.9 26.3 ± 0.2 -5.7 ± 0.3 -37.8 ± 1.15 1.2 ± 0.1 1.2 ± 0.4 36.9 ± 7.5 
MnL4NH3+ 6.35 ± 0.7 25.1 ± 0.1 -7.4 ± 0.8 -32.2 ± 0.7 0.2 ± 0.3 1.6 ± 2.0 39.9 ± 38.1 
 
Relaxometric measurements and NMRD profiles to assess the efficiency as MRI CA 
As a reminder, the relaxivity is defined as the increase of the water proton relaxation rate 
induced by one mmol per liter of paramagnetic complexes. Longitudinal (r1) relaxivities were 
measured at 37°C and respectively 0.47 T (20 MHz) and 1.41 T (60 MHz) (Table 3). They are 
lower than that of the commercially available gadolinium complexes (the data for Gd-DOTA are, 
for comparison, 3.5 s-1·mM-1 at 20 MHz and 3.1 s-1·mM-1 at 60 MHz and 37°C), as expected part 
due to the intrinsic lower number of unpaired electrons for manganese (5) compared to that for 
gadolinium (7). The relaxivities could however be increased by grafting of the complexes on 
macromolecular entities that would reduce the tumbling rate of the complex, which enhances the 
interaction time between the nuclear magnetic moments of the water protons and the orbital one 
of the paramagnetic complex during an echo time of the NMR radiofrequency field pulse 
sequence, and therefore the spin relaxation mechanism.19 This is envisaged as outlook of this 
work in a near future.  
NMRD profiles were performed for the four pyclen-based manganese complexes in order to 
evaluate the efficacy of each complex according to the magnetic field or frequency used. The 
fitting of these profiles according to the theory of Solomon and Bloembergen allows extracting 
important parameters to understand this efficacy such as the rotational correlation time (𝜏𝜏R) or 
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“tumbling time”, the electronic relaxation time at zero field (𝜏𝜏SO) and the correlation time that 
modulates electronic relaxation (𝜏𝜏V).37–39 Among the four complexes studied, MnL1H, has a r1 
NMR dispersion profile below the other curves, especially at low field. This difference can be 
ascribed to the electronic properties of the complex which are slightly less favorable than for the 
other ones: 𝜏𝜏SO is indeed lower compared to the values of the three other complexes. This is 
again encouraging for the future studies where we plan to graft other molecules thanks to the arm 
present on the pyridine moiety. (Figure 6)  
 
 
Figure 6. 1H NMRD profiles at 37°C for Mn2+-complexes, showing the longitudinal relaxivity at 
varying proton Larmor frequency (aka varying magnetic field). The straight lines show the 
theoretical fitting based on the theory of Bloembergen and Solomon.37–39 
Table 3. Results of the theoretical fitting of 1H NMRD profiles at 37°C with Bloembergen and 
Solomon’s theory using the MINUIT minimization software. Parameters, such as the distance of 
closest approach (dNMR) and the water diffusion coefficient (D) governing the outer sphere 
mechanism, or the distance between the coordinated proton of the water molecule and the 
manganese ion (r) related to the inner sphere mechanism, can be set constant during the fitting 
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procedure thank to their prior determinations along the study of the manganese complex 
properties.37–39 The values of q and τM used were also predetermined thanks to their separate 
evaluation described above, thereby allowing to evaluate the rotational correlation time (𝜏𝜏R), the 
electronic relaxation time to ground level at zero magnetic field (𝜏𝜏SO) and the correlation time 
that modulates electronic orbital relaxation (𝜏𝜏V) at 37°C. 
 MnL1H MnL2COO- MnL3CH MnL4NH3+ 
dNMR (nm) [a] 0.36 0.36 0.36 0.36 
D (m2·s-1) [a] 3.3×10-9 3.3×10-9 3.3×10-9 3.3×10-9 
r (nm) [a] 0.28 0.28 0.28 0.28 
𝜏𝜏R (ps) [b]  48.7 ± 3.8 57 ± 5.2 65.6 ± 0.85 59 ± 0.6 
𝜏𝜏M (ns) [a]  6.5  6.1 8.4 6.35 
𝜏𝜏SO (ps) [b]  119 ± 19.2 155 ± 29.5  224 ± 31.6 272 ± 6760.0 
𝜏𝜏v (ps) [b]  5.7 ± 1.2 3.4 ± 0.7 8.7 ± 8.0 3.1 ± 61.6 
q [a] 1 1 1 1 
r1 at 20MHz 
(s-1·mmol-1·L)  
2.6 2.7 3.2 2.9 
r1 at 60MHz 
(s-1·mmol-1·L)  
2.4 2.6 3.3 2.4 
[a] Parameters pre-set at constant values during the fitting procedure [b] Parameters obtained 
by the fitting of NMRD profiles with Bloembergen and Solomon’s model. 
 
Transmetalation evaluation 
It is now well-established that the kinetic inertness of a complex is a more important parameter 
than its intrinsic thermodynamic stability for in vivo applications. In order to define the stability 
of the manganese complexes against the most important endogenous divalent metal cations 
present in body fluids (Zn2+, Cu2+, Ca2+, Mg2+), a transmetalation study was performed in the 
presence of Zn(II) as exchanging metal cation. The choice of Zn2+ as challenger to assess the in 
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vivo transmetalation behavior of the Mn(II) complexes was governed by the following 
considerations:40,41 i) none of the four competitive endogenous cations is paramagnetic and 
therefore does respond to NMR; ii) Zn2+ is the second most abundant transition metal in the 
human body (33 ppm) after Fe3+ (60 ppm); iii) for a given exogenous ligand, complexes of Zn2+ 
as well as Cu2+ have generally higher stability than the corresponding Mn2+ complex as ascribed 
to LFSE effect (ligand field stabilization energy), whereas alkaline earth ions Ca2+ and Mg2+, 
although present at higher concentrations in blood plasma than Zn2+, form generally less stable 
complexes with the exogenous ligands generally studied for Mn2+ due to their absence of d 
electronic orbitals; iv) the concentration of Zn2+ in blood is higher compared to that of Cu2+ (5 to 
100 times higher).42 As previously described by us,41,43 the transmetalation rate was assessed by 
measuring the progress of the proton relaxivity at 37°C and 20 MHz. The method consists in 
using a solution of the Mn-complexes at concentration 2.5 mM in phosphate buffer in the 
presence of an equimolar amount of zinc chloride. The proton longitudinal relaxation time (T1) is 
then measured in order to determine paramagnetic relaxation rate R1p as a function of time. 
Indeed, when the exchange between Mn2 and Zn2+ takes place, a precipitate of manganese 
phosphate (Mn3(PO4)2) is formed. This process leads to increase of T1 and thus decrease of R1p 
compared to its initial value R1p(t=0), as ascribed to decrease of paramagnetic ion concentration 
in solution.  
The results (Figure 7) are similar for all the Mn complexes studied and show, during the first 
day, a small fast yet transient increase of the ratio R1p/R1p(t=0), which could be due to the 
presence of transient polynuclear species coordinated to both Mn2+ and Zn2+. This step is 
followed by a decrease of about 50% of the relaxation rate due to the formation of the insoluble 
solid as explained previously. This decrease is however quite slow (t1/2 half-life of approximately 
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1350 min) and we can notice that at the first measurement of the second day, the relaxation rate 
reached 80% of the initial value of relaxation rate. As a conclusion, even though this study 
highlights a lack of kinetic stability towards the transmetalation with zinc ions after a long time, 
we can be confident for the use of those complexes in vivo given their expected fast clearance 
from the organism. Further in vitro toxicity and in vivo pharmacokinetic studies will however be 
necessary in the future to definitively demonstrate the biosafety of these paramagnetic MRI CAs.  
 
Figure 7. Evolution of the normalized paramagnetic longitudinal relaxation rate in order to 
evaluate the transmetalation kinetics between manganese and zinc ions for the four Mn2+-
complexes: MnL1H (triangles), MnL2COO- (stars), MnL3CH (circles) and MnL4NH3+ (squares). 
Experiment was performed during 5 days in phosphate buffer at 20 MHz and 37°C. The 
concentration of Mn-complexes and of competing Zn(II) salt used is 2.5 mM, which is much 
higher than its normal physiological level (∼10 µM).44   
 
 Phantom images 
 
Author manuscript of article published in Inorganic Chemistry 2021 doi: 10.1021/acs.inorgchem.0c03120  
 24 
As a proof of concept of the use of these manganese-complexes as MRI CAs, phantom 
MRI images were recorded both at preclinical (9.4 T) and clinical magnetic field (1 T), for each 
manganese complex at a concentration of 0.5 mM and compared with Gd-DOTA at the same 
concentration and with water (Figure 8). As expected, the images are highlighted for the four 
Mn-complexes compared to water but their contrast is less enhanced than with Gd-DOTA. 
Among the Mn-complexes, we can also notice a smaller highlighting effect for MnL1H, which 
can be related to its smaller relaxivity because of the absence of the arm on the pyridine structure 
(Table 3).  
 
Figure 8. Phantom images recorded at approximately 37°C under two different magnetic fields 
(1 T and 9.4 T) of each Mn2+-complex at a concentration of 0.5 mM compared with a 
commercial Gd-complex, Gd-DOTA, at the same concentration, and with pure water.  
Table 3. Values of longitudinal relaxivity calculated from the water proton relaxation time T1 
measured at approximately 37°C under a field of 9.4T (400 MHz). 
 MnL1H MnL2COO- MnL3CH MnL4NH3+ Gd-DOTA 
      
r1 (s-1·mM-1) 
9.4T, 37°C  
2.8 ± 0.1 2.7 ± 0.1 3.1 ± 0.1 2.95 ± 0.1 3.2 ± 0.1  
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Conclusions and perspectives   
 
Four novel pyclen-based complexing agents were synthesized and the molecular structure of 
intermediated compounds after each step of the synthesis was characterized. The corresponding 
manganese complexes were prepared and fully characterized by NMR relaxometry methods to 
evaluate the parameters governing their properties and efficacy as paramagnetic MRI contrast 
agents. This characterization is important in order to evaluate if the complexes have an efficacy 
close to the commercial gadolinium complexes, and could potentially replace them on market, if 
they pass further evaluation of their bio-safety.  
Although these Mn-based compounds have been shown to be slightly less effective than the 
marketed Gd-based compounds as ascribed to lower magnetic moment of the metal, the potential 
of these pyclen-based chelating compounds remains high. Their relaxivity could indeed be 
improved by different ways. Firstly, it will be possible to play on the rotational correlation time 
of the complex by blocking them in a nanostructure either organic (e.g. micelle or vesicle) or 
inorganic (e.g. silica nanoparticle), while keeping sufficiently small hydrodynamic size and 
stealthness to allow rapid clearance when injected in systemic circulation (which is a prerequisite 
for CAs used in clinics). Moreover, the additional chemical functions on the pyridine moiety will 
allow conjugation to biologically relevant vectors such as peptides or antibodies in order to target 
specific pathologies. Finally, on the basis of reported results, further improved kinetic inertness 
of the Mn2-complexes might be obtained in future by replacing the two acetate complexing 
groups by non-ionizable groups such as amides; in this case, the positive charge on the resulting 
cationic Mn2 complexes could be protective against acid-assisted dissociation, although grafting 
of neutral macromolecules might be necessary in that case to insure stealthness against 
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adsorption of blood plasma proteins. It will nevertheless be important to verify that the presence 
of those amide functions does not increase too much the residence time in the inner sphere of the 
coordinated water molecule. As a conclusion, these preliminary results show very encouraging 
properties of pyclen derivatives for MRI contrast properties, although further study is necessary 
to demonstrate that they can replace gadolinium complexes in clinical diagnosis of diseases 
(cancers, strokes…) by MRI.   
 
Experimental section  
 
Materials  
Chemical and physical measurements:  
The NMR spectra (1H, 13C, COSY, DEPT) were recorded at 298K and reported in ppm. 
(Bruker® AVANCEII-500 at 500 MHz, Bruker® AVANCE NEO at 400 MHz or Bruker® 
AVANCE NEO at 600 MHz). The multiplicity of the peaks is defined as s (singlet), d (doublet), 
t (triplet) and m (multiplet). The reactions were monitored by mass spectrometry (Waters®, ZQ-
2000) and all the compounds were characterized by mass spectrometry (Waters® ZQ-2000, 
Waters® QDa, Waters® Quattro Premier or Waters® QTofUs). The ESI-LRMS was performed 
on 3200 QTrap (AB Sciex). The pH was controlled by Mettler Toledo® fiveEasy pH/mV. The 
relaxometry and NMRD profiles measurements were performed on Bruker® MiniSpec at 20 and 
60 MHz at 37°C and on a fast field cycling (FFC) relaxometer between 0.02 and 40 MHz 
(Spinmaster, Stelar®, Italy). 17O NMR measurements were performed on a Bruker® 
AVANCEII-500 at 67.8 MHz. The MRI measurements were performed on 1T (Bruker® ICON) 
and 9.4T (Bruker® Biospec) with a Rapid Acquisition with Relaxation Enhancement sequence 
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(RARE) (TE = 12 ms, TR = 350 ms, resolution = 156 x 146 microns, RARE factor = 2, 2 or 4 




Chemical material and methods:  
The flash chromatography was performed on Biotage® flash chromatography using pre-




Synthesis of the lower part  
 
2-Nitro[N(2{2[(2-nitrophenyl)sulfonylamino]ethylamino})-ethyl]benzenesulfonamide 
compound 2: It is synthesized according to the protocol of Devreux et al.31 
 
Benzyl N,N-bis(2-((2-nitrophenyl)sulfonylamino)ethyl)carbamate compound 3: DIPEA 
(7.7 mL, 44.2 mmol, 1.2 eq) is added to a solution of disulfonamido amine 2 (17.6 g, 37.1 mmol) 
in THF (100 mL), followed by benzyl chloroformate (6.3 mL, 44.1 mmol, 1.2 eq) in one portion. 
The reaction is stirred overnight during which insoluble matter appeared. The mixture is 
concentrated to dryness. The crude material is taken up in CH2Cl2 (100 mL), and is washed with 
water (4 x 30 mL). The organic layer is dried then concentrated to dryness to afford the desired 
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compound 2 as a brown oil (21.2 g, 34.8 mmol). Yield 94%. 1H NMR (CDCl3, 400 MHz) δ 
(ppm): conformed to reported data of Kim et al.45 
 
 Di-tert-butyl 2,2'-(((((benzyloxy)carbonyl)azanediyl)bis(ethane-2,1-diyl))bis 
(azanediyl))diacetate compound 5b: A suspension of the previously prepared compound 3 
(1.61 g, 2.65 mmol) with potassium carbonate (810 mg, 5.86 mmol, 2.2 eq) in acetonitrile 
(22 mL) is refluxed for 15 minutes. tert-Butyl bromoacetate (900 µL, 6.09 mmol, 2.3 eq) is 
added in one portion. The reaction is monitored by MS and/or TLC (Cyclohexane/AcOEt 1/1 v/v, 
UV detection). After 1.5h, total conversion of both the starting triamine 3, and of the mono-N-
alkylated intermediate 4a is observed leading to the di-N-alkylated disulfonamide 4b. The 
reaction mixture is cooled, and a second portion of potassium carbonate (1.60 g, 11.92 mmol, 
4.4 eq) is added, followed by thiophenol (810 µL, 7.94 mmol, 3.0 eq) in one portion. The 
reaction is monitored by MS and/or TLC (Cyclohexane/AcOEt 1/1 v/v, UV detection: 
CH2Cl2/MeOH 97.5/2.5 v/v, UV and ninhydrin stain detection). After 2.5h, total conversion of 
the intermediate compounds 4b and 5a is obtained. The reaction mixture is allowed to cool to 
room temperature. Insoluble matter is filtered off through Celite®, and the organic filtrate is 
concentrated to dryness. The resulting canary yellow colored oil is purified by chromatography 
on silica gel (CH2Cl2/MeOH 10/0 to 8/2 v/v) and led to the desired product 5b as an orange oil 
(1.051 g, 2.26 mmol). Yield 85%. 1H NMR (CDCl3, 400 MHz) δ (ppm): 1.44 (s, 18H, -tBu); 
2.73-2.90 (m, 4H, -N-CH2-CH2-N-); 3.22-3.36 (m, 4H, -CH2-CO2tBu); 3.44 (broad s, 4H, -N-
CH2-CH2-N); 5.12 (s, 2H, -CH2-Ph); 7.26-7.38 (m, 5H, CHAr). 13C NMR (CDCl3, 100 MHz) 
δ (ppm): 28.1 (-tBu); 47.7, 48.0, 48.2, and 48.5 (-N-CH2-CH2-N); 51.2 (-CH2-CO2tBu); 67.3 (-
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CH2-Ph); 81.6 (CquattBu); 127.9, 128.0, and 128.6 (CHAr); 136.7 (CquatPh); 156.4 (-N-CO2Ph); 
171.0 (-CO2tBu). 
 
Synthesis of the upper parts   
 
2,6-Bis(bromomethyl)pyridine compound 6a: It is synthesized according to the protocol of 
Dioury et al.28  
 
Ethyl ((2,6-bis(bromomethyl)pyridin-3-yl)oxy)acetate compound 6b: It is synthesized 
according to the protocol of Devreux et al.31  
 
Synthesis of MnPy(COO-)2-H (Compound MnL1H) 
  
Benzyl 3,9-bis(2-tert-butoxy-2-oxo-ethyl)-3,6,9,15-tetrazabicyclo[9.3.1] pentadeca-
1(14),11(15),12-triene-6-carboxylate compound 7a: Solid Na2CO3 (480 mg, 4.53 mmol, 4 eq) is 
added to a solution of diamine lower part 5b (530 mg, 1.14 mmol) with 
2,6-bis(bromomethyl)pyridine 6a (401 mg, 1.52 mmol, 1.3 eq) in acetonitrile (115 mL). The 
suspension is refluxed until completion of the reaction (MS and/or TLC monitoring; 1 hour). The 
insoluble matter is filtered off, and the filtrate is concentrated to dryness. The crude material 
obtained is purified by chromatography on silica gel (CH2Cl2/MeOH, 100/0 to 98/2 v/v). to give 
the desired compound 7a as a thick oil (253 mg, 0.445 mmol). Yield 39%. 1H NMR (CDCl3, 
400 MHz) δ (ppm): 1.43, and 1.44 (2 s#, 18H, -tBu); 2.68-2.90 (m, 4H, -N-CH2-CH2-N-); 3.16-
3.27 (broad t, J 7-7.80 Hz, 4H, -N-CH2-CH2-N-); 3.34, and 3.41 (2 broad s#, 4H, -N-CH2-); 3.91-
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4.06 (m, 4H, -N-CH2-); 5.01 (s, 2H, -CH2-Ph); 7.13-7.31 (m, 7H, Ph, and -CH2-C(N)-CH=CH); 
7.61 (t, J 7.6 Hz, 1H, -CH2-C(N)-CH=CH). #Double signal that may be due to rotamers 
(carbamate bond: free-rotation obstruction) 13C NMR (CDCl3, 100 MHz) δ (ppm): 28.2 (-tBu); 
44.9, and 45.3$ (-N-CH2-CH2-N-); 51.6, and 52.1$ (-N-CH2-CH2-N-); 59.0, and 59.2$ (-N-CH2-); 
60.0, and 60.2$ (-N-CH2-); 66.8 (-CH2-Ph); 81.2 (CquattBu); 122.9 (-CH2-C(N)-CH=CH); 127.6, 
127.8, 128.4 (3 CHArPh); 137.0 (CquatPh); 137.5 (-CH2-C(N)-CH=CH); 156.1, 157.3, 157.7& 
(NCO2, and 2 CquatPyr); 170.6 (CO2). $Although the symmetrical structure, each 13C appears to 
be diastereotopic; that may be due to rotamers from the carbamate bond (free-rotation 
obstruction). &Broad and small signal. 
 
 tert-Butyl 2-{9-[2-(tert-butoxy)-2-oxoethyl]-3,6,9,15-tetraazabicyclo[9.3.1] pentadeca-
1(14),11(15),12-trien-3-yl}acetate compound 8a: Compound 7a (240 mg, 0.42 mmol) is 
solubilized in EtOH following by the addition of Pd/C (24 mg). The solution is stirred 10 days 
under under H2 at atmospheric pressure. Insoluble material is filtered through Celite® and the 
filtrate is concentrated at relatively high temperature to eliminate the toluene which is the by-
product to give the desired compound 8a. The crude product is directly engaged in the next 
synthesis step. 1H NMR (CD3OD, 500 MHz) 𝛿𝛿 (ppm) : 1.46 (s, 18H, -tBu); 2.64-3.01 (broad s, 
4H, -N-CH2-CH2-N-); 3.31 (broad t, J 5.3 Hz 4H, -N-CH2-CH2-N-); 3.51 (s, 2H, N-CH2-N-); 




yl]acetic acid compound 10a: Compound 8a (10 mg; 0.023 mmol) is solubilized in 
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dichloromethane (1 mL) and stirred following by the addition of trifluoroacetic acid (1 mL). 
Overnight, the solution is concentrated and washed two times with diethylether (4 mL) to give 
the desired compound 10a (12 mg, 0.018mmol). Yield 79.8 % (determined by weighing). 1H 
NMR (CD3OD, 500 MHz) 𝛿𝛿 (ppm): 3.11 (broad t, J 5.21 Hz, 4H, -N-CH2-CH2-N-); 3.21 (broad 
t, J 5 Hz, 4H, -N-CH2-CH2-N-); 3.62 (s, 4H, -N-CH2-N-); 4.12 (s, 4H, -CH2-CO2tBu); 7.25 (d, J 
7.71 Hz, 2H, CH=CH-CH=); 7.79 (t, J 7.7 Hz, 1H, -CH=CH-CH=). 
 
2-(12-{[(2-aminoethyl)carbamoyl]methoxy}-9-(carboxymethyl)-3,6,9,15-
tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl)acetic acid manganese compound 11a: A 
solution of MnCl2.4H2O (7 mg, 0.035 mmol) in water (0.5 mL) is added dropwise to a solution 
of compound 10a (12 mg, 0.018 mmol) in water (1 mL). The pH is adjusted and maintained to 
5 < pH < 6 with 0.1 M aqueous solution of NaOH. The mixture is warmed at 40°C overnight. 
The presence of free Mn2+ is revealed by the colorimetric test with orange xylenol. The aqueous 
mixture is treated with Chelex resin, then freeze-dried to give the desired compound 11a. ESI-
MS (C15H20MnN4O4): m/z 398.09 [M+Na]+. 
 
Synthesis of MnPy(COO-)2-OCH2CO2- (Compound MnL2COO-) 
 
Benzyl 3,9-bis(2-tert-butoxy-2-oxo-ethyl)-12-(2-ethoxy-2-oxo-ethoxy)-3,6,9,15-
tetrazabicyclo[9.3.1]pentadeca-1(14),11(15),12-triene-6-carboxylate compound 7b: Solid 
Na2CO3 (466 mg, 4.40 mmol, 4 eq) is added to a solution of triamine lower part 5b (513 mg, 
1.10 mmol) with dibromomethyl compound 6b (444 mg, 1.21 mmol, 1.1 eq) in acetonitrile 
(110 mL). The suspension is refluxed until completion of the reaction (MS and/or TLC 
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monitoring; 1 hour). The insoluble matter is filtered off, and the filtrate is concentrated to 
dryness. The crude material obtained is purified by chromatography on silica gel 
(CH2Cl2/MeOH, 100/0 to 98/2 v/v) to give the desired compound 7b as a thick oil (471 mg, 
0.702 mmol). Yield 64%. 1H NMR (CDCl3, 400 MHz) δ (ppm): 1.27 (t, 3H, J 7.1 Hz, -Et); 1.45 
(s, 9H, -tBu); 1.48 (s, 9H, -tBu); 2.68-3.01 (m, 4H, -N-CH2-CH2-N-); 3.20-3.55 (m, 8H, -N-CH2-
CH2-N- (4H) and -N-CH2-); 3.95 (d, 2H, J 10.2 Hz, -N-CH2-); 4.19 (d, 2H, J 7.3 Hz, -N-CH2-); 
4.24 (d, 2H, J 7.1 Hz, -Et); 4.66 (s, 2H, -O-CH2-CO2-Et); 5.04 (s, 2H, -CH2-Ph); 7.04 (d, 
J 8.4 Hz, 1H, -CH2-C(N)-CH=CH-C(OR) -C); 7.18 (broad dd,££ 4J ≈ 3J 8.4 Hz, 1H, -CH2-C(N)-
CH=CH-C(OR) -C); 7.24-7.37 (m, 5H, -Ph). ££That resonance looks like a broad unsymmetrical 
triplet that can be attributed to a doublet of doublet with similar 3J (8.4 Hz, vicinal coupling) and 
4J coupling constants; the unusually high long-range 4J coupling constant (≈ 8.4 Hz) may be due 
to a pseudo W-conformation of the four sigma bonds between the two coupled 1H. 13C NMR 
(CDCl3, 100 MHz) δ (ppm): Caution: Some of the 13C are doublet due to the presence of 
rotamers. 14.2 (CH3_Et); 28.3 (CH3_2 -tBu); 44.6, 45.0, 45.5, 46.1$$ (2 -N-CH2-CH2-N-); 51.3, 
51.8, 52.0, 52.4$$ (2 -N-CH2-CH2-N-); 54.5, 54.6$ (-N-CH2-); 58.7, 58.9, 59.5 (3 -N-CH2-); 61.6 
(CH2_Et); 65.8 (-O-CH2-CO2-Et); 66.8 (-CH2-Ph); 81.0, 81.2 (2 CquattBu); 119.8, 119.9$ 
(CHArPyr); 123.8 (CHArPyr); 127.6, 127.8, 128.5 (3 CHArPh); 137.1 (CquatPh); 147.6, 151.8£, 
156.2 (NCO2, and 3 CquatPyr); 166.4, 168.3, 170.7-170.9& (3 CO2). $Double signal for the 
assigned 13C (rotamers); $$Double signal for each of the assigned 13C; &Broad and small signal; 
£Higher signal than the adjacent one; may account for several 13C. 
 
Ethyl 2-({3,9-bis[2-(tert-butoxy)-2-oxoethyl]-3,6,9,15-tetraazabicyclo[9.3.1] pentadeca-
1(15),11,13-trien-12-yl}oxy)acetate compound 8b: Compound 7b (55 mg, 0.082 mmol, 1 eq) is 
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solubilized in MeOH (20 mL) followed by the addition of Pd/C (6 mg). The solution is placed 
under H2 at atmospheric pressure and is stirred during 24h. Insoluble material is filtered through 
Celite® and the filtrate is concentrated at relatively high temperature to eliminate the toluene 
which is the by-product to give the desired compound 8b. The crude product is directly engaged 
in the next synthesis step. 1H NMR (CD3OD, 500 MHz) 𝛿𝛿 (ppm) : 1.28 (t, J 7.15 Hz, 3H, -CH2-
CH3); 1.46 (s, 9H, -tBu); 1.47 (s, 9H, -tBu); 3.07-3.12 (m, 4H, -N-CH2-CH2-N-); 3.16-3.21 (m, 
4H, -N-CH2-CH2-N-); 3.47 (s, 2H, -N-CH2-N-); 3.52 (s, 2H, -N-CH2-N-); 3.96 (s, 2H, -N-CH2-
CO-); 4.17 (s, 2H, -N-CH2-CO-); 4.23 (q, J 7.11 Hz, 2H, -O-CH2-CH3); 4.82 (s, 2H, -O-CH2-
CO-); 7.11 (d, J 8.42 Hz, 1H, -O-C=CH-CH=C-); 7.27 (d, 1H, J 8.43 Hz, -O-C=CH-CH=C-). 
 
2-({3,9-Bis[2-(tert-butoxy)-2-oxoethyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-
trien-12-yl}oxy)acetic acid compound 9: Compound 8b (481 mg, 0.90 mmol, 1eq) is solubilized 
in ethanol (7mL) and put under stirring. A solution of aqueous 1M NaOH is then added (1 mL, 1 
mmol, 1.1 eq). The solution is stirred during few hours, then concentrated under vacuum. The 
crude product is purified by flash chromatography on RP18 column (MeOH/H2O from 3/7 to 
10/0 v/v) to give the desired compound 9 (310 mg, 0.61 mmol). Yield 67% (determined by 
weighing). 1H NMR (CD3OD, 500 MHz) 𝛿𝛿 (ppm): 1.47 (s, 9H, -tBu); 1.47 (s, 9H, -tBu);  2.99-
3.06 (m, 4H, -N-CH2-CH2-N-); 3.11-3.16 (m, 4H, -N-CH2-CH2-N-); 3.26 (s, 2H, -N-CH2-N-); 
3.53 (s, 2H, -N-CH2-N-); 3.94 (s, 2H, -N-CH2-CO-); 4.18 (s, 2H, -N-CH2-CO-); 4.46 (s, 2H, -O-
CH2-CO-); 7.05 (d, 1H, J 8.41 Hz, -O-C=CH-CH=C); 7.11 (d, J 8.41 Hz, 1H, -O-C=CH-CH=C).  
 
2-{[3,9-Bis(carboxymethyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-12-
yl]oxy}acetic acid 10b: The compound 9 (10 mg, 0.019 mmol) is solubilized in dichloromethane 
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(1 mL) and put under stirring followed by the addition of trifluoroacetic acid (1 mL). The 
solution is stirred overnight. It is then concentrated and washed two times with diethyl ether (4 
mL) to give the desired compound 10b as TFA salt. The crude product is directly engaged in the 
next synthesis step. 1H NMR (CD3OD, 500 MHz) 𝛿𝛿 (ppm): 3.08-3.14 (broad s, 4H, -N-CH2-CH2-
N-); 3.18-3.26 (broad m, 4H, -N-CH2-CH2-N-); 3.62 (s, 2H, -N-CH2-N-); 3.69 (s, 2H, -N-CH2-
N-); 4.06 (s, 2H, -N-CH2-CO2H); 4.27 (s, 2H, -N-CH2-CO2H); 4.82 (s, 2H, -O-CH2-CO2H); 7.19 
(d, 1H, J 8.29 Hz, -O-C=CH-CH=C-); 7.34 (d, 1H, J 8.43 Hz , -O-C=CH-CH=C-). 
2-(12-{[(2-aminoethyl)carbamoyl]methoxy}-9-(carboxymethyl)-3,6,9,15-
tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl)acetic acid manganese compound 11b: A 
solution of MnCl2.4H2O (6 mg, 0.03 mmol) in water (0.5mL) is added dropwise to a solution of 
compound 10b (11 mg, 0.016 mmol) in water (1 mL). The pH is adjusted and maintained to 
5 < pH < 6 with 0.1 M aqueous solution of NaOH. The mixture is warmed at 40°C overnight. 
The presence of free Mn2+ is revealed by the colorimetric test with orange xylenol. The aqueous 
mixture is treated with Chelex resin, then freeze-dried to give the desired compound 11b. ESI-
MS (C17H22MnN4O7): m/z 472.10 [M+Na]+. 
 
Synthesis of MnPy(COO-)2-OCH2CO2NHCH2CCH (Compound MnL3CH) 
 
Tert-butyl 2-{9-[2-(tert-butoxy)-2-oxoethyl]-12-{[(prop-2-yn-1-yl)carbamoyl] methoxy}-
3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl}acetate compound 12: 
Compound 9 (10 mg, 0.019 mmol) and HBTU (15 mg,  0.04 mmol, 2.1 eq) are solubilized in 
CH2Cl2 (2 mL) followed by the addition of propargylamine (2 µL, 0.031 mmol, 1.6 eq) and 
DIPEA (8 µL, 0.047 mmol, 2.47 eq). The solution is stirred during few hours at room 
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temperature then the middle is washed three times with water (5 mL) to give the desired 
compound. Yield (crude) >90% (determined by weighing). The crude product is directly engaged 
in the next synthesis step. 1H NMR (CDCl3, 500 MHz) 𝛿𝛿 (ppm): 1.45 (s, 18H, -tBu) 2.22 (t, J 
2.56 Hz, 1H, -C≡CH); 3.03-3.11 (m, 4H, -N-CH2-CH2-NH-); 3.21-3.28 (m, 4H, -N-CH2-CH2-
NH); 3.43 (s, 2H, -C-CH2-N-); 3.47 (s, 2H, -C-CH2-N-); 3.92 (s, 2H, -N-CH2-CO-); 4.08-4.16 
(m, 4H, -N-CH2-CO- and -NH-CH2-C-); 4.54 (s, 2H, -O-CH2-CO-); 7.02 (d, J 8.39 Hz, 1H, -O-
C=CH-CH=C-); 7.07 (d, J 8.39 Hz, 1H, -O-C=CH-CH=C-).  
 
2-[9-(Carboxymethyl)-12-{[(prop-2-yn-1-yl)carbamoyl]methoxy}-3,6,9,15-
tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl]acetic acid compound 13: Compound 12 
(119 mg, 0.218 mmol) is solubilized in CH2Cl2 (3 mL) and stirred followed by the addition of 
trifluoroacetic acid (3 mL). Overnight, the solution is concentrated and washed two times with 
diethyl ether to give the desired compound 13 as TFA salt. The crude product is directly engaged 
in the next synthesis step. 1H NMR (CD3OD, 500 MHz) 𝛿𝛿 (ppm): 2.60 (t, J 2.54 Hz, 1H, -
C≡CH); 3.10-3.16 (m, 4H, N-CH2-CH2-NH-); 3.19-3.25 (m, 2H, N-CH2-CH2-NH-); 3.25-3.30 
(m, 2H, N-CH2-CH2-NH-); 3.69 (s, 2H, -N-CH2-C-); 3.80 (s, 2H, -N-CH2-C-); 4.03 (d, J 2.56 
Hz, 2H, -NH-CH2-C); 4.15 (s, 2H, -N-CH2-COOH); 4.38 (s, 2H, -N-CH2-COOH); 4.71 (s, 2H, -




tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl)acetic acid manganese compound 14: A 
solution of MnCl2.4H2O (4 mg, 0.02 mmol) in water (0.5 mL) is added dropwise to a solution of 
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compound 13 (8 mg, 0.01 mmol) in water (1 mL). The pH is adjusted and maintained to 5 < 
pH < 6 with 0.1 M aqueous solution of NaOH. The mixture is warmed at 40°C overnight. The 
presence of free Mn2+ ions is revealed by the colorimetric test with orange xylenol. The aqueous 
mixture is treated with Chelex resin, then freeze-dried to give the desired compound 14. ESI-MS 




Synthesis of MnPy(COO-)2-OCH2CO2NHCH2CH2NH2 (Compound MnL4NH3+) 
 
Benzyl 12-[2-(2-aminoethylamino)-2-oxo-ethoxy]-3,9-bis(2-tert-butoxy-2-oxo-ethyl)-3,6,9,15-
tetrazabicyclo[9.3.1]pentadeca-1(14),11(15),12-triene-6-carboxylate compound 15: A solution of 
the previously prepared ethyl ester 7b (470 mg, 701 mmol) in ethylenediamine (2.3 mL, 
34.4 mmol, 50 eq) is stirred at room temperature until completion of the reaction (MS 
monitoring; 1 hour). The crude medium is diluted in CH2Cl2 (15 mL) and is washed with water 
(3 mL). The organic layer is dried then concentrated to dryness. The resulting material is purified 
by chromatography on silica gel (CH2Cl2/MeOH/NH3 7N in MeOH 95/2.5/2.5 to 90/5/5 v/v/v) 
and led to the desired product 15 as a beige solid (279 mg, 0.407 mmol). Yield 58%. 1H NMR 
(CDCl3, 400 MHz) δ (ppm): 1.34-1.53 (m, 18H, -tBu); 1.94 (broad s, 2H, -NH2); 2.55-2.66 (m, 
2H, -N-CH2-CH2-N-); 2.66-2.88 (m, 4H, -N-CH2-CH2-N(2H) and -CH2-NH2); 2.96-3.09 (m, 2H, 
-N-CH2-CH2-N-); 3.28-3.50 (m, 8H, -CO-NH-CH2-, -N-CH2- (4H), -N-CH2-CH2-N- (2H)); 3.89 
and 3.93 (2 br s$, 2H, -N-CH2-); 4.02 and 4.05 (2 br s$, 2H, -N-CH2-); 4.56 (broad s, 2H, -O-
CH2-); 5.01 (s, 2H, -CH2-Ph); 7.16 (d, J 8.4 Hz, 1H, -CH2-C(N)-CH=CH-C(OR)-C); 7.21-7.33 
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(m, 6H, -CH2-C(N)-CH=CH-C(OR)-C, and Ph); 8.15, and 8.25$ (2 broad t, 1H (≈53/47), -CO-
NH-). $Double signal due to two conformers (double-bond character of the amide bond: cis and 
trans conformations) or two rotamers (free rotation obstruction due to Cbz steric hindrance). 
13C NMR (CDCl3, 100 MHz) δ (ppm): Caution: As previously observed for the precursor 7b, 
nearly all of the 13C are doublet due to the presence of rotamers (double bond character of the 
amide bond and/or free-rotation obstruction of the carbamate bond). 28.18, 28.23 (CH3_2 -tBu); 
41.8, 42.1, 42.2, 42.3 (-CO-NH-CH2-CH2-NH2)#; 44.9, 45.4 (-N-CH2-CH2-N-)#; 50.9, 51.0, 51.6, 
51.8 (2 -N-CH2-CH2-N-)#; 54.2, 54.5 (-N-CH2-)#; 58.8, 59.0, 59.1, 59.4 (-N-CH2-CH2-N-, and 3 -
N-CH2-); 66.9 (-CH2-Ph); 67.2 (-O-CH2-); 81.2, 81.47, 81.52 (2 CquattBu)$; 119.65, 119.68 (-
CH2-C(N)-CH=CH-C(OR)-C)#; 124.97, 125.01 (-CH2-C(N)-CH=CH-C(OR)-C)#; 127.57, 
127.65, 127.83, 127.90, 128.46 (3 CHArPh)$; 136.85, 136.94 (CquatPh)#; 145.9, 146.1, 149.2, 
149.7, 151.7, 151.8, 155.9, 156.0 (-N-CO2, and 3 CquatPyr)#; 168.21, 168.24, 170.4, 170.6, 170.7, 
170.8 (2 CO2, and CONH)#. #Double signal for (each of) the assigned 13C (rotamers); $Double 
signal for at least one of the assigned 13C. 
 
2-(12-{[(2-Aminoethyl)carbamoyl]methoxy}-9-(carboxymethyl)-3,6,9,15-
tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl)acetic acid compound 16a.xHBr: A 
concentrated solution of the fully protected precursor 15 previously prepared (210 mg, 
0.307 mmol) in CH2Cl2 (0.250 mL) is diluted in acetic acid (2 mL). A solution of hydrogen 
bromide in acetic acid (33% w/w, 0.500 mL) is then added and a white precipitate appeared 
instantly. The mixture is vigorously stirred and heated at 70°C for 7 hours and then at room 
temperature overnight. The dark orange supernatant is removed by suction and the solid material 
is washed several times with Et2O until a clear wash is obtained. The organic solvents are 
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completely removed first under reduced pressure and then by freeze-drying after solubilization in 
water to give the desired compound as a brownish solid material (200 mg, 0.288 mmol on the 
basis on an estimated PM 693.38 for 3HBr/4HBr hydrobromide forms in 85/15 mol/mol at 
pH 0.747). Yield (crude) 94%. The crude material can be purified by chromatography on RP18 
(CH3CN/H2O 9/1 v/v) after raising the pH from 0.7 to about 4.5 (NaOHaq) and leads to the 
desired product as a beige solid (115 mg, 0.221 mmol on the basis on an estimated PM 516.97 
for .1HBr/.0HBr/.2HBr hydrobromide forms in 73/15/12 mol/mol/mol at pH 4.547). Yield 72%. 
1H NMR (D2O, pH<1) δ (ppm): 3.14 (broad t, 2H, -CH2-NH2-); 3.20-3.38 (m, 6H, -N-CH2-CH2-
NH-); 3.44 (broad s, 2H, -N-CH2-CH2-N-); 3.56 (broad t, 2H, -CO-NH-CH2-); 4.00 (s, 2H, -N-
CH2-); 4.06 (s, 2H, -N-CH2-); 4.47 (s, 2H, -N-CH2-); 4.65 (s, 2H, -N-CH2-); 4.80* (2H, -O-CH2-
CO-N-); 7.57 (d of AB system, J 8.4 Hz, 1H, CHAr);7.71 (d of AB system, J 8.4 Hz, 1H, CHAr). 
*Fully superimposed with the deuterated solvent (deduced from corr 1H/13C 2D experiment). 13C 
NMR (D2O, pH<1): 36.6 (-CO-NH-CH2-); 39.0 (-CH2-NH2-); 43.7, 43.9 (2 -N-CH2-CH2-NH-); 
51.0, 52.2 (2 -N-CH2-CH2-NH-); 54.0, 56.7, 57.1, 57.4 (4 -N-CH2-); 67.3 (-O-CH2-CO-N-); 
125.0 (2 CHAr); 142.1, 144.3, 152.0 (3 CquatPyr); 170.6, 172.2, 172.3 (2 CO2, and -CO-NH-). 
 
2-(12-{[(2-aminoethyl)carbamoyl]methoxy}-9-(carboxymethyl)-3,6,9,15-tetra 
azabicyclo[9.3.1]pentadeca-1(15),11,13-trien-3-yl)acetic acid manganese compound 17:  
A solution of the previously prepared ligand 16a.xHBr (~0.17 mmol) in deionized H2O (3 mL) 
is adjusted to pH ~ 5.5 with an aqueous solution of NaOH. Manganese(II) chloride tetrahydrate 
(33 mg, 0.168 mmol) is added in one portion which immediately induced a decrease of pH down 
to 2.2. The pH is carefully adjusted again to ~ 5.7 with aqueous NaOH. The resulting mixture is 
stirred at room temperature for 5 minutes. A monitoring by MS indicated a total conversion to 
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the desired manganese complex with no trace of free ligand 8. The pH is then raised up to ~ 7.5 
(NaOHaq) and stirring maintained overnight. The fine brown precipitate formed is filtered off 
over a 0.2 µm membrane (PALL®, Acrodisc®). The filtrate is concentrated by freeze-drying. The 
solid obtained (113 mg) is purified by chromatography on RP18 (MeOH/H2O 9/1 v/v) and leads 
to the desired product 17 as a beige solid (108 mg, x H2O.y HCl or NaCl probable form(s)). ESI-
LRMS m/z: 492.2 [M+H]+, 514.1 [M+Na]+.  
 
 
Determination of Mn2+ concentration for relaxometric and 17O measurements 
 
The detection of free manganese ions is performed with a test of xylenol orange: 300 µL of 
phosphate or acetate buffer, one drop of pyridine, one drop of the compound solution and one 
drop of xylenol orange (0.1 g per 100 mL). The color is pink or orange for phosphate or acetate 
buffer respectively without manganese ions and gets purple when free manganese ions are 
present. The solution is then treated with a Chelex® 100 resin (sodium form) to eliminate those 
free ions.  
The Mn2+ concentration determination is performed either by relaxometry and ICP-AES, on 
samples digested with nitric acid. The first method consists in measuring the water paramagnetic 
longitudinal relaxation rate of the digested solution at 20 MHz. It is then compared to the 
paramagnetic relaxation rate of a 1 mM solution of free manganese ions (equal to 8 s-1 at 20 
MHz and 37°C) in order to extract the manganese concentration.4 To ensure the results, ICP-
AES measurements are also performed on Varian Liberty Series II, based on a Mn2+ calibration 
curve. The concentrations obtained respectively from ICP-AES or relaxometry methods are 
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respectively 1.80 and 1.76 mM (MnL1H), 5.09 and 5.66 mM (MnL2COO-), 7.85 and 8.05 mM 
(MnL3CH), and 2.47 and 2.35 mM (MnL4NH3+).  
 
Relaxometry measurement  
 
The longitudinal relaxation times (T1) are determined at 20 MHz and 60 MHz on Bruker® 
Minispec mq20 and mq60 relaxometers. These measurements allow to obtain the relaxivity of 







 s-1·mM-1 (3) where 
𝑅𝑅1 (water)d = 0.2826 s−1 at 37°C.   
The NMRD profiles were recorded at 37°C and 25°C on a Stelar® fast field cycling (FFC) 
relaxometer (Stelar, Mede, Italy) and the least-squares fitting of the data was performed using a 
home-made program (Fitting2000) and equations from the Solomon and Bloembergen (SBM) 
theory. 
 
Temperature dependent 17O NMR measurements 
 
The transverse 17O relaxation rates (R2=1/T2) are measured in aqueous solutions of each 
manganese complex (MnL1H; 2.06 mM, MnL2COO-; 2.58 mM, MnL3CH: 2.05 mM and 
MnL4NH3+: 1.21 mM) in the temperature range 7 – 81°C, on a Bruker® AvanceII-500 (11.75 T, 
67.8 MHz) spectrometer. The temperature is calculated according to a previous calibration with 
ethylene glycol and methanol. Proton decoupling is applied during all the acquisitions. 
Transverse relaxation times (T2) are obtained by the measurement of the signal width at mid-
height. For the determination of τM, the data are presented as the reduced transverse relaxation 
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rate R2R=1/T2R= 55.55R2P /([Mncomplex]·q), where [Mncomplex] is the molar concentration of the 
complex, q is the number of coordinated water molecules and R2P is the paramagnetic transverse 
relaxation rate obtained after subtraction of the diamagnetic contribution from the observed 
relaxation rate. The treatment of the experimental data is performed as already described and the 
fitting of the data is obtained with a home-made program.46 
For the determination of the number of coordinated water molecules, the data are presented as 
the transverse relaxivity r2 = R2P/[Mncomplex] where the concentration of the Mncomplex is 




The transmetalation is performed in a phosphate buffer solution (pH 7.06, salt concentrations 
below) and on the Bruker® Minispec mq20 relaxometer. 300 µL of a solution of each complex at 
a concentration of 2.5 mM is prepared in phosphate buffer solution ([NaH2PO4] = 0.026 mol/L et 
[Na2HPO4] = 0.041 mol/L) and 3 μL of a solution 250 mM of ZnCl2 (1 eq) is added in the 
studied Mn-complexes solutions. Then, the longitudinal relaxation time (T1) is measured as a 
function of time to obtain the evolution of R1p following the equation: 𝑅𝑅1
p = � 1
𝑇𝑇1 10−3
� −
𝑅𝑅1 (water)d  (4) where 𝑅𝑅1 (water)d = 0.2826 s−1 is the diamagnetic contribution. During 5 days, the 
ratio R1p/R1p (t=0) is determined at regular intervals to evidence the transmetalation kinetics 
induced by the presence of zinc cations, which leads to a release of manganese ions and their 
precipitation by phosphates. This release induces formation of a precipitate of Mn3(PO4)2, which 
leads to a decrease of the paramagnetic relaxation rate.41 
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